153 related articles for article (PubMed ID: 27897303)
1. [Pharmacoeconomic study of the treatment of advanced Parkinson's disease].
Vivancos-Matellano F; Garcia-Ruiz AJ; Garcia-Agua Soler N
Rev Neurol; 2016 Dec; 63(12):529-536. PubMed ID: 27897303
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson's disease in the UK and Germany.
Walter E; Odin P
J Med Econ; 2015 Feb; 18(2):155-65. PubMed ID: 25348011
[TBL] [Abstract][Full Text] [Related]
3. The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson's disease.
Lowin J; Sail K; Baj R; Jalundhwala YJ; Marshall TS; Konwea H; Chaudhuri KR
J Med Econ; 2017 Nov; 20(11):1207-1215. PubMed ID: 28895769
[TBL] [Abstract][Full Text] [Related]
4. Cost-utility analysis of levodopa carbidopa intestinal gel (Duodopa) in the treatment of advanced Parkinson's disease in patients in Scotland and Wales.
Kalabina S; Belsey J; Pivonka D; Mohamed B; Thomas C; Paterson B
J Med Econ; 2019 Mar; 22(3):215-225. PubMed ID: 30484353
[TBL] [Abstract][Full Text] [Related]
5. A cost-effectiveness analysis of levodopa/carbidopa intestinal gel compared to standard care in late stage Parkinson's disease in the UK.
Lowin J; Bergman A; Chaudhuri KR; Findley LJ; Roeder C; Schifflers M; Wood E; Morris S
J Med Econ; 2011; 14(5):584-93. PubMed ID: 21728911
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of treatment of Parkinson's disease with entacapone in the United States.
Palmer CS; Nuijten MJ; Schmier JK; Subedi P; Snyder EH
Pharmacoeconomics; 2002; 20(9):617-28. PubMed ID: 12141889
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off.
Findley LJ; Lees A; Apajasalo M; Pitkänen A; Turunen H
Curr Med Res Opin; 2005 Jul; 21(7):1005-14. PubMed ID: 16004667
[TBL] [Abstract][Full Text] [Related]
8. Pramipexole and levodopa in early Parkinson's disease: dynamic changes in cost effectiveness.
Noyes K; Dick AW; Holloway RG;
Pharmacoeconomics; 2005; 23(12):1257-70. PubMed ID: 16336019
[TBL] [Abstract][Full Text] [Related]
9. Short-term cost and health consequences of duodenal levodopa infusion in advanced Parkinson's disease in Sweden: an exploratory study.
Kristiansen IS; Bingefors K; Nyholm D; Isacson D
Appl Health Econ Health Policy; 2009; 7(3):167-80. PubMed ID: 19799471
[TBL] [Abstract][Full Text] [Related]
10. Cost analysis of the treatments for patients with advanced Parkinson's disease: SCOPE study.
Valldeoriola F; Puig-Junoy J; Puig-Peiró R;
J Med Econ; 2013; 16(2):191-201. PubMed ID: 23035627
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness of Device-Aided Therapies in Parkinson's Disease: A Structured Review.
Smilowska K; van Wamelen DJ; Pietrzykowski T; Calvano A; Rodriguez-Blazquez C; Martinez-Martin P; Odin P; Chaudhuri KR
J Parkinsons Dis; 2021; 11(2):475-489. PubMed ID: 33386813
[TBL] [Abstract][Full Text] [Related]
12. Protocol of a randomized open label multicentre trial comparing continuous intrajejunal levodopa infusion with deep brain stimulation in Parkinson's disease - the INfusion VErsus STimulation (INVEST) study.
van Poppelen D; Sisodia V; de Haan RJ; Dijkgraaf MGW; Schuurman PR; Geurtsen GJ; Berk AEM; de Bie RMA; Dijk JM
BMC Neurol; 2020 Jan; 20(1):40. PubMed ID: 32005175
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of neurostimulation in Parkinson's disease with early motor complications.
Dams J; Balzer-Geldsetzer M; Siebert U; Deuschl G; Schuepbach WM; Krack P; Timmermann L; Schnitzler A; Reese JP; Dodel R;
Mov Disord; 2016 Aug; 31(8):1183-91. PubMed ID: 27506638
[TBL] [Abstract][Full Text] [Related]
14. [Cost analysis in Italy of various strategies for the treatment of Parkinson disease in the advanced phase].
D'Ausilio A; Marconi S; Antonini A; Tamma F; Valzania F; Berto P
Recenti Prog Med; 2003 Nov; 94(11):484-93. PubMed ID: 14679916
[TBL] [Abstract][Full Text] [Related]
15. Cost-utility model of rasagiline in the treatment of advanced Parkinson's disease in Finland.
Hudry J; Rinne JO; Keränen T; Eckert L; Cochran JM
Ann Pharmacother; 2006 Apr; 40(4):651-7. PubMed ID: 16569799
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness of Deep Brain Stimulation for Advanced Parkinson's Disease in the United States.
Pietzsch JB; Garner AM; Marks WJ
Neuromodulation; 2016 Oct; 19(7):689-697. PubMed ID: 27491661
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of pramipexole in Parkinson's disease in the US.
Hoerger TJ; Bala MV; Rowland C; Greer M; Chrischilles EA; Holloway RG
Pharmacoeconomics; 1998 Nov; 14(5):541-57. PubMed ID: 10344917
[TBL] [Abstract][Full Text] [Related]
18. Motor features and response to oral levodopa in patients with Parkinson's disease under continuous dopaminergic infusion or deep brain stimulation.
Elia AE; Dollenz C; Soliveri P; Albanese A
Eur J Neurol; 2012 Jan; 19(1):76-83. PubMed ID: 21645174
[TBL] [Abstract][Full Text] [Related]
19. [Device-aided therapies in advanced Parkinson's disease].
Timofeeva AA
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(12):54-60. PubMed ID: 28139627
[TBL] [Abstract][Full Text] [Related]
20. Real life cost and quality of life associated with continuous intraduodenal levodopa infusion compared with oral treatment in Parkinson patients.
Lundqvist C; Beiske AG; Reiertsen O; Kristiansen IS
J Neurol; 2014 Dec; 261(12):2438-45. PubMed ID: 25270681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
